Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics. Accessed 24 Apr 2023. In: Search for FDA guidance documents. U.S. Food and Drug Administration, 2018

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9. https://doi.org/10.1056/NEJMoa1809064.

Article  CAS  PubMed  Google Scholar 

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377:829–38. https://doi.org/10.1056/NEJMoa1704795.

Article  CAS  PubMed  Google Scholar 

Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38:3138–49. https://doi.org/10.1200/JCO.20.00147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33. https://doi.org/10.1056/NEJMoa1706450.

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–64. https://doi.org/10.1200/JCO.2006.08.1620.

Article  CAS  PubMed  Google Scholar 

Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, et al. Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS wild-type metastatic colorectal cancer: the open-label, randomized, phase III TAILOR trial. J Clin Oncol. 2018;36:3031–9. https://doi.org/10.1200/JCO.2018.78.3183.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9. https://doi.org/10.1200/JCO.2007.14.9930.

Article  CAS  PubMed  Google Scholar 

Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808–20. https://doi.org/10.1016/S1470-2045(20)30156-X.

Article  CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905. https://doi.org/10.1056/NEJMoa1915745.

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Article  CAS  PubMed  Google Scholar 

Bogaerts K, Komarek A, Lesaffre E. Survival analysis with interval-censored data: A practical approach with examples in R, SAS, and BUGS. Boco Raton: CRC Press; 2017.

Book  Google Scholar 

Law CG, Brookmeyer R. Effects of mid-point imputation on the analysis of doubly censored data. Stat Med. 1992;11:1569–78. https://doi.org/10.1002/sim.4780111204.

Article  CAS  PubMed  Google Scholar 

Nishikawa M, Tango T. Behavior of the Kaplan-Meier estimator for deterministic imputations to interval-censored data and the Turnbull estimator. Jpn J Biom. 2003;24:71–94. https://doi.org/10.5691/jjb.24.71.

Article  Google Scholar 

Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29–41. https://doi.org/10.2307/2530286.

Article  Google Scholar 

Turnbull BW. The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc B (Methodol). 1976;38:290–5. https://doi.org/10.1111/j.2517-6161.1976.tb01597.x.

Article  Google Scholar 

Gentlemen R, Greyer CJ. Maximum likelihood for interval censored data: consistency and computation. Biometrika. 1994;81:618–23. https://doi.org/10.2307/2337135.

Article  Google Scholar 

Wellner JA, Zhan Y. A hybrid algorithm for computation of the nonparametric maximum likelihood estimator from censored data. J Am Stat Assoc. 1997;92:945–59. https://doi.org/10.1080/01621459.1997.10474049.

Article  Google Scholar 

Anderson-Bergman C. An efficient implementation of the EMICM algorithm for the interval censored NPMLE. J Comp Graph Stat. 2017;26:463–7. https://doi.org/10.1080/10618600.2016.1208616.

Article  Google Scholar 

Anderson-Bergman C. icenReg: regression models for interval censored. Data. Version 2.0; 8. https://CRAN.R-project.org/package=icenReg

Project data sphere; 2022. https://data.projectdatasphere.org/projectdatasphere/html/home. Accessed 24 Apr 2023.